28381262-Sunpharma-analysis
32
0
0
Full text
(2) | |. |. SUMMARY | ô dameal aalysis| | |
(3) | ||
(4) | |
(5) || |
(6) || | || || | |
(7) | || | | | | || | | | || | | || | | | | | |
(8) | | | | | | |
(9) |
(10) | | |
(11) ||| | ||
(12) | | | | | | | | | | ||
(13) || |||| || || |||| || || | || | || | | | I his assigmemyself has made a aemp o aalyze he fiaial performae of S Pharmae ials Id sries limied. | ||
(14) | | | | |Idia eoomy||Id sry seario |
(15) | | ||
(16) | | | | |ompay fiaial performae ad raios aalysis. !
(17) | || | |
(18) | |
(19)
(20) ||||. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(21) | |. |. INDIAN ECONOMY| | | |
(22) ||| | | | || | |"##"|!| |
(23) |
(24) |fo rh larges|| | ||p rhasig power pariy|$%%%&|
(25) ||
(26) |'( |)
(27) ||*|| || || || || ||*|||| ||
(28) ||
(29) || | || |
(30) |+ | || | ||||
(31) || | |
(32) ||
(33)
(34) ||||
(35)
(36) || ||||
(37) |||| || || || |||||||| | | |
(38) |
(39) || |
(40) | | |
(41) || |
(42) | |,| | ||||||
(43)
(44) || || - || |||| ||"##"||!
(45) | | || |||| || || || || |||||| |||. | || ||!
(46) | | ||
(47) | | | |"##"|'
(48) |
(49) | | | ||
(50) | || ||
(51) | || |
(52) |
(53) | ||
(54) |+ | | ||
(55) | | | /| | |011#|
(56) | || |
(57) | | || || | ||!
(58) ||| | | | | || | | |
(59) || | | |
(60) |
(61) || | |
(62) | | ||2 |
(63) |
(64) | | | | | || || | | |$ &|
(65) ||)
(66) |3| || |/
(67) || | |
(68) |
(69) ||
(70) | |
(71) | | || | |) || | || ||
(72) | | || | || | |
(73) | | || |4| | | |
(74) | | | . |$.&| | | |
(75) |||"0|| | |011#5| | || ||+ | | |!
(76) | ||||
(77) | ||
(78) |
(79)
(80) || | |
(81) || || |2 |
(82) || |
(83) |.| | | |6| |7 |$6 7&| | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(84) | |. |. || |* |01"1|
(85) |
(86) | ||
(87) | |
(88) | ||011#| |$-&"8|| || | |011#| ||$-&"9|| | !
(89) | |
(90)
(91) | |
(92) | | | || | | ||
(93) ||
(94) ||
(95) | |||| ||
(96) ||||
(97) | ||
(98) |4 |: ||;| || ||| || | | | | || || || |
(99) | ||
(100)
(101) || || |- || |) |
(102) |
(103) | | || || | | | |
(104) || | | | !
(105) | ||+ || || |011<-1#| | |
(106) |
(107) | |
(108) || |
(109) | | || | | |
(110) | -| ||
(111) | | | |!
(112) | |
(113) |
(114) ||
(115) |+ | |
(116)
(117) |
(118) || | |
(119) | |7 |011<|!
(120) | | | |
(121) | | | |||| ||
(122) | | | | || | | | | | % | | | |!
(123) | | |
(124)
(125) |
(126) ||
(127) | | ||
(128) |||
(129) ||||||!
(130) | | |
(131) | | | | |
(132) || | ||
(133) | | ||
(134)
(135) | . | | | |
(136) ||
(137) | |011<-1#| | | |. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(138) | |. |. INDIAN PHARMACEUTICAL INDUSTRY. |
(139) | |
(140) || | | || |'(|="1| | | |h rak|| || |||| ||
(141) || ||||13h | || || || || | | | || | ||>0|?|| |+ | | | |'(|=| "8| ||01""| | 7|
(142) | | ||
(143) |
(144) | | |
(145) | | | |'(|=| 9@@| | ||
(146) |
(147) ||| || | || |9#11| | | |
(148) ||
(149) | |
(150) | | ||!
(151) |
(152) ||| | |
(153) || || |
(154) |
(155) | | | 6
(156) ||
(157) ||% ||% || ||
(158)
(159) |||| || || ||* ||011@||
(160) || || || | | |/)| | | |
(161) | | |
(162) |
(163) | |
(164) || | |
(165) | | | | || | || |
(166) | || || |
(167) | | || - | |4+(
(168) 3 | | |
(169) | |
(170) ||
(171) | |
(172) |
(173) | |
(174) |
(175) | | | | || |
(176) ||
(177) ||
(178) | | Cora researh ad pharmae ial o so rig||||
(179) |||| || ||
(180) %
(181) | ||) || || || || |||||| || |||| | | | | |'(|=|91 |
(182) | |
(183) | | | |
(184) |'(|=|A-"1| | | | | | |Dr. Reddy¶s Lab, S Pharmae ials Ld, Cipla, Rabaxy, e|
(185) | || |
(186) | | | | |
(187) | |
(188) | | | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(189) | |. |. || ||||.||||: || ||$.: &|||| /: || $ |/||: || &B:.||$: || ||. &||
(190) |||||| |||| | || |||| - ||||
(191)
(192) || || || ||.
(193) ||
(194) |
(195) ||
(196) || |||| ||
(197) || ||||
(198) |||||| || || || |
(199) |
(200) | | |
(201) | || || | | | | | | | || | | || |) 42| |#?||011<-01"9| |'(=|"9@| | |+ |
(202) |
(203) | | | | | |+|
(204) |
(205) | | | |||
(206) |C |.
(207) ||"1-""?| |
(208) |8-@?|
(209) ||| |
(210) ||>-<?| | | |+ | | ||
(211) || ||
(212) | | 3|
(213) | ||| || | |
(214)
(215) | || | || | ||| |01@1|
(216) || | |
(217) | | ||81-@#||A1D|| | | ||"8| |09|| 1>| |"#| |!
(218) | | |
(219) | ||
(220) | |
(221)
(222) | ||
(223) || |
(224)
(225) |
(226) || | |
(227) |
(228) |4:%|!
(229) | ||
(230) | | |
(231) ||
(232) | | | |. | |4 ||| | | || | | || | | |*|
(233)
(234) |
(235) || | | ||91?| | ||01"0||@?|$'(=|9&| | | | 6|
(236) | || || B
(237) | | |
(238) | | | | | | |
(239) | |
(240) | | | | | |011<|
(241) | | |
(242) || || |
(243) | || | | O |
(244) | | |% |
(245) | || || || | | | |4+(
(246) 3 ||:|2E| || | | | ||| ||"11| | | | |6|+ ||
(247) || || | | || | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(248) | |. |. ||
(249) | | | | |. : | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(250) | |. |. TARGETTING EMERGING MARKETS| | | !
(251) | |'(|| '| || |
(252) | | || | | ||| 2)(|$ |2 | |)
(253) ||(
(254) | &| | ||
(255) | | !
(256) | |
(257) | |
(258) | |$ | | ||) 42|| "0-"@?||011#-01"8&| || || ||| ||| | | | || | |!
(259) | ||| | ||
(260) ||
(261)
(262) | | |
(263) | | | | |
(264) ||| |
(265) | ||| |. Ireasig iovaor ± geeri a isiios/ parerships: | ||2+||:
(266) |(| |011<| ||| | |
(267) | ||| | || ||| | | 2 | | |% - %||) |O | | |
(268) | | | |4(3||:|2E|||"11| | |
(269) | | |
(270)
(271)
(272) |
(273) |||
(274) || |
(275) | | 6| || | | |
(276) | | | | ||
(277) |+ |||6||| | | | | || | |
(278)
(279) | |
(280) |
(281) | | |01"0-"9|. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(282) | |. |. SWOT ANALYSIS Oô PHARMA SECTOR. STRENGTHS:| | ) | |
(283) | | ( ||-| ||. OPPORTUNITIES|. | ) |
(284) || |. | |+ | |. | 3 ||-| ||. | |
(285)
(286) | |. | |F|
(287) |. | /| |
(288) | |. | % | |
(289) - |
(290) |. | 4 |. | ;
(291) - | || |. | : | | | |. | ;
(292) | || |. | | |. | 6-|| ||. | % || | | | ) | |. | WEAKNESSES | O| |
(293) | ||
(294) | |$ |0?&| | O|| | | | . | | | O|2F:| | | || | | || | | O|
(295)
(296) |+ | | % || | |. | ) | |F|
(297) | | : | | | THREATS| | (| || | | ) ||/)| | ! ||| | | | |$!2%(&| | 7 |(|| |
(298) | | /- | | || | |. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(299) | |. |. ôUTURE SCENARIO|. | | !
(300) ||| |
(301) | || |
(302) || | | |
(303) |
(304) |
(305) | ||
(306) || | | |*||' |( | || | | | !
(307) || | |
(308) ||| |
(309) | | || | ||| | | |||2F:| ||| | |) || | || | |
(310) ||6
(311) | | || |'(=|8@ | |011@|
(312) | | | |+ | | | |'(=| "11| | |
(313) |+ ||| | !
(314) || || |||| ||
(315) || || |||| || |||| |% | | | ||| |
(316) ||) |
(317) | | | || | |
(318) | ||01-0@?||||| | | '(=|"1-"01 ||011@| | |
(319) || |
(320) | || |
(321) | | || | | |+| || | ) |2
(322) |7 |$)27&|| | | ||'(=|""<| |%|| | | | | | | |'(=|9<1| ||01"1||/)| | |
(323) | |
(324) | || | | |2F:| |
(325) |. | | | | |2F:| | |
(326) || | | | +| + ||| | || | ||+ || ||||||
(327) || |||| || ||||+ |||| || || | | |2F:|. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(328) | |. |. CHALLENGES: PHARMA SECTOR|. | | | | || | || | ) | | | | 4 | | | .| | | % | |F|
(329) | | | | |) | | ( |
(330) | | | | | |% |% |. | 2 | | || | | | |$*C&||| | |. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(331) | |. |. ANALYSIS Oô COMPANY Overview: !
(332) |
(333) | | | | ||| | || | | || G| | ||
(334) | |. | | | |
(335) |
(336) |||| || | | | |!
(337) | | || | |
(338) 5| | ||| | |
(339) |H H|||||| |!
(340) |$ ||
(341) &||| | |
(342) | | | |
(343) | : ||
(344) |||+ | | ||
(345) | || | | ||| || | || | | |
(346) | || | | | |
(347) | ||
(348) ||
(349) | | | | |
(350) | | |
(351) | || |
(352) | | ||| | | || | |
(353) | || ||
(354) | | | | | ||| || || |
(355) | || | ||| | || | Wha Is ô dameal Aalysis? . | | |
(356) | || || || ||
(357) | | || | | | | | | |
(358) | | |||
(359) | |
(360) | ||
(361) | | |!
(362) |||| || | |
(363) ||| ||
(364) |
(365) | | || |
(366) | || | !
(367) | ||
(368) | | | | || || | | | | | | || |
(369) | ||||
(370) || | | 6
(371) | || |||H - |+ H||
(372) | ||
(373) | | | |
(374) ||
(375) || | ||
(376) | || |
(377) | | |||| | |
(378) | |
(379) | | | |
(380) ||
(381) | | | | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(382) | |. |. !
(383) |. | || | | | | |
(384) | | | ||| | |
(385) | | | | | +| | |||
(386) |
(387) | | |||| . | || |
(388) | | | |
(389) |||| | | | | ||
(390) | | || |
(391) ||
(392) | | |
(393) || ||
(394) |
(395) || |
(396) | | Wha Is Tehial Aalysis?| !
(397) | | ||
(398) || | || |
(399) | |. || | |
(400) || | || |!
(401) | || | | | || | | | | | |
(402) ||
(403) | | | | |
(404) ||. | | || * ||
(405) ||| | ||
(406) | | |
(407) |||| | ||
(408) | |(|||
(409) | |
(410) | |
(411) | || || | || ||
(412) | ||||
(413) | |+ | ||
(414) | || | | |
(415) | |
(416) ||
(417) | | |' | | |
(418) | | ||
(419)
(420) || | | |-|
(421) ||
(422) |
(423) | | || | | | ||
(424) | |
(425) | || | |
(426) |
(427) | |
(428) || |
(429) | || !
(430) | ||
(431) | | |||
(432) | G|| "|||||!
(433) | | |
(434) || 0|||||% || | || 9|||||; | | | | | !
(435) | ||| ||| |
(436) |
(437) | | |!
(438) | | | || | +- | |+| ||
(439) | || | | | | |+| || | |
(440) |
(441) | ||| | || || || |
(442) | | || | |
(443) | ||+|
(444) |
(445) | || | || | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(446) | |. |. ô dameal Vs. Tehial Aalysis: !
(447) | || | ||
(448) | | |
(449) ||
(450)
(451) | |
(452) | | | || |
(453) | || |
(454) | | ||| || |
(455) | | | | | | | | . | ||
(456) |
(457) |
(458) || | | ||| |O | | |
(459) | ||
(460) |
(461) | |
(462) | |
(463) | | |
(464) | ||
(465) |
(466) || | || | |
(467) | | | | | | | | | | | |. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(468) | |. |. SUN PHARMACEUTICALS INDUSTRIES LIMITED
(469) ( | %
(470) | | O | | | |
(471) | |
(472) | | | | 91| | ( | %
(473) | | | |
(474) | | | | | ( |
(475) | | | | |
(476) |
(477) | | | |
(478) | | | | | | |. ( |%
(479) || |+ ||| |
(480) | |@| | |"#<9||
(481) | | | ( |
(482) |
(483) | | | | | | | | |
(484) ||
(485) |
(486) |+| | | | || |
(487) || | | || |( |%
(488)
(489) |
(490) |
(491) | |
(492) ||
(493) |
(494) ||
(495) |
(496) | | ||| | |
(497) | | ||| | (
(498) | |
(499) || |
(500) | | | ||
(501)
(502) | | ||
(503) || ||
(504) | -"##A||( |%
(505) |
(506) | || || |
(507) || | | |
(508) 5| | ||
(509) ||
(510) |'(|: || )|%
(511) |O|)/|; |$|| |)
(512) |)| + |4 &||
(513) ||
(514) | || | |;| || || |7
(515) |'(||) |/*|'(| |( |%
(516) |
(517) |
(518) || | || || | | | | ||(% 2)|
(519)
(520) | | ||
(521) | | |+
(522) |. Key Milesoes pos 1996G| | 1997|G| ||! |/ |:
(523) |%
(524) |O | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(525) | |. |. | 1998: | |G| ||/ %
(526) |. 1999 : || |O| | 2000: ||%|: |)|O | | 200|G| | ( |%
(527) | | | |)| |AA?| |011>|
(528) | |
(529) |
(530) |>@?| || | | !
(531) | | | |;| |$
(532) |
(533) |*|%
(534) | &| || |'(.: |'3|;2 |(
(535) | |))| | /C( ||) | /C | ( |%
(536) | ||)
(537) | | |%
(538) +|%
(539) |
(540) | ||| + |+ |
(541) | |011>|| | | || ||| | |
(542) || ||
(543) | %|| | |
(544) ||||
(545) |'(.: | 2005: |( |%
(546) | || | | |7
(547) |'(||
(548) | ||)/|; || C |%
(549) | ( |%
(550) | |
(551) | | || || |O||
(552) |'(| : | | | |/|*| |:|011@|| : (
(553)
(554) |
(555) |):| |
(556) | F,| ||
(557) |,|| |
(558)
(559) || | ||011@|| ( |%
(560) | | ||.| |
(561) | |011| |$||
(562) | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(563) | |. |. '(:|"| &| | |!
(564) | |
(565) |
(566) | | |@||
(567) |
(568) ||
(569) || | | 2006:| | |
(570) | || | |
(571) | || | | | |||| 2007:| |) |
(572) | ||
(573) | | |
(574) | | || ||(% 2)| |
(575) ||| | ||
(576) | |+
(577) | | |
(578) | | |
(579) || ||| | ||011>|| |
(580) | | | | | | | |!|%
(581) | |O |$! 27.|% |(
(582) &|| |. | |
(583) |
(584) | | || | |
(585) |'(||)||=8@8| |!
(586) |-
(587) || | | |!|
(588)
(589) ||| | || 2008:| ||/|011<|( |%
(590) | |
(591) | | |"11?|
(592) | |)
(593) |)
(594) || || | || || | |
(595) ||| | |!|!
(596) | || | || | | | || | |
(597) |'(| | |. ô dameal Aalysis: | SHAREHOLDING PATTERN AT SUN PHARHARMACEUTICALS LTD. AS ON 31ST MARCH, 2010 : Table -3 Type Of Shareholder. % Of Shares |. SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(598) | |. |. Promoers ad gro p. 63.71. M al ô ds or UTI. 3.52. ôiaial Isi ios or baks. 2.29. ôII. 18.1. Corporaes/HNIs. 5.89. Reail Ivesors. 6.9. Toal. 100. Shareholdig Paer ) B;/ A?. 2 | A?. . "<? . | || 0? |. || '! 8?. % | | A8?. CONSISTANT PERôORMANCE IN DOMESTIC MARKET: "| ( |%
(599) | |
(600) | +
(601) | || | |$ | || |&|
(602) || |
(603) ||9@?|( |
(604) | || |) 42||0<?||.,1@.,1#| || | ||
(605) || | || | |
(606) |( E| |
(607) | | || |9| | ||@1?|| | |8@1||( | |/"| ||
(608) | |%
(609) |/ | ) |7
(610)
(611) |: ||7
(612) |!
(613) | || | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(614) | |. |. | | | 0|: ||
(615)
(616) ||( E| || |
(617) | | | | | | | ||| |
(618) || |
(619) | |+ | | |. | | | |. SUN PHARMA PERôORMANCE ôROM JUN 0 TO JUN 09 :. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(620) | |. |. ? . ÃÃ ÃÃÃ ÃÃ. . ÃÃÃ. Ã. Ã
(621). Ã. Ã. Ã. Ã. Ã. Ã. ÃÃ. Ã. . ÃÃ . ?
(622) . ÃÃÃ. . Reaso for sok prie hike i J e 1999 o Ja 2000"&|!
(623) |)|
(624) | | |
(625) ||+ | |( |%
(626) | + |
(627) | ||( |%
(628) | | |##0<?| |-|( | %
(629) | + | 0&|( |%
(630) | |O |
(631) ||
(632) | ||
(633) | |%| : |)|O | 9&|!
(634) |||@
(635) || | | ||
(636) || | | | |
(637) ||08>?| |/|0111| |0><?| | /|011"|$724|2 |)
(638) | |/|0111||011"&|.| 4|
(639) | | | | | |( |%
(640) | |
(641) | |011| | ||0110|. Reaso for sok prie hike i April 200 | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(642) | |. |. ( |%
(643) | |
(644) | | | |)|
(645) | E|
(646) | |A9"8?|. Reaso for sok prie hike i 2007 "&| ( |%
(647) | |!||8| | |. KEY ôACTORS IN SUN PHARMA¶S PERôORMANCE:. DESPITE CORACO¶S SETBACK, US SALES TO GROW ôROM SUN¶S OWN ôILINGS: | Y | ( E| | |
(648) |'(|)E|99| || | ||
(649) |'(|.: | || ||4%| ||| | |!
(650) |'(|.: || |
(651) |
(652) | | | ||| || | |
(653) |'(| |
(654) | |)E| || | |
(655) |'(|.: | |!
(656) | | | || | ||
(657) |99| | ||| |
(658) ||)E|| | |
(659) |||'(=|""0| |.,1#|| |)E|0@| /: | || | ||| |||| ñ | : |
(660) | ||)|( E|| | | |
(661) ||
(662) |'(| |)| || | | || |$ &|
(663) |+| |||( E| | | |
(664)
(665) |
(666) ||||
(667) |'(| .: |( ||)|
(668) |
(669) |"1<| /: | |||
(670)
(671) |( | |
(672) |<9| /: | | || |) | |!
(673) | | | || | |'(=|A| |
(674) | | | | |
(675) | ||
(676) | |( | | | | | | |
(677) ||
(678)
(679) | |||| | | | | | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(680) | |. |. | LAUNCH Oô TECHNICALLY COMPLEX PRODUCTS HAS ENSURED CONTINUING CASH ôLOW BEYOND THE LIMITED PERIODG| Y | ( E| |
(681) ||
(682) |
(683) ||
(684) |+| | |
(685) |'(|
(686)
(687) | | | |
(688) || |
(689) |+ | | ||
(690) |||( |
(691) || +|| |
(692) | |$% -'(=|09&||| | |$
(693) -'(=|<1&| |
(694) |
(695) | | | | | |
(696) |+| || | ñ | 4 |' |
(697) | |:|E1@| | || |
(698) |
(699) |
(700) | | | |
(701) | |4 |% +|
(702) | | |
(703) ||"<1-|+ |
(704) | |||'(=|981|
(705) | |
(706) |
(707) | | |
(708) |"<1|+ | | | |
(709) | |'(=|0@|
(710) || | |% +| |+ | | |:|E"1|
(711) |
(712) E| |+ | || |* |E"0| 6 | ( |
(713) | | | /: || | +|I2|
(714) |
(715) |'(|.: ||| 7 E| |( |
(716) | || ||6
(717) || || || |
(718) |'(|.: |( | | || || ||
(719) |'(=|0A| | |
(720) |+ | | |* |J"1| +|I2| | || | | | | | 6
(721) |
(722) |||
(723) | | | | || |
(724) |
(725) ||
(726) |+ | |
(727) |
(728) | | | | |
(729) || |
(730) || |. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(731) | |. |. ACQUIRES ASSETS WITH AN AIM TO GENERATE HIGH ROI | | ( |%
(732) |
(733) |
(734) |
(735) | | | | |
(736)
(737) | | ||| | |||| | | || ||
(738) ||( E| | | |)| |"##>|
(739)
(740) |
(741) ||- ||
(742) || ||'(=|1<|( E|
(743) | | | || | | )E| | |0119|.|.,1#|)| |||'(=|9">|
(744) || ||'(=|0"| | ( E|
(745) | | | || | |; |$ |)
(746) &|
(747)
(748) || | | %|| | |
(749) |'(=|A| | | | |
(750) |'(|
(751)
(752) |
(753) | | | | | | | | || |O||
(754) | || | ||
(755) |'(| |) ||
(756) |: ||/|*||'(=|09| | ( |
(757) | | | |
(758) | | ||| |)
(759) | O|| || | || || | |
(760) || | |!|. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(761) | |. |. ôiaial AalysisG|!|@| Profi ad Loss. 2|| |. Pari lars Mar 2010 No. of Mohs| 12| Gross Sales 3925.50| O|G | | 1| | OG|(|2 | 1| OG| + | A9#11| 9<A"@@1| Ne Sales EXPENDITURE : | B:| |( | -286.80| 2| |) | 1897.0| %|F|. |) | @1881| |) | "88<81| 7
(762) | | 08>@>1| +| 4|| | @8A@1| +| ( ||: | 91@091| +| | +| ">#"1| OG|%- | 1| +|) | 0A<#811| Toal Expedi re "">0"@1| Operaig Profi (Exl OI) 7
(763) || 188.90| 7 |% | "9@>181| | 0>>1| "9@80>1| PBDT : | @<<A1| % | |!+ |F| "0#@8"1| + | | + ||B| 1| +| % | |!+| "0#@8"1| % ||!+| 301.20| "0A@0#1| Profis Afer Tax | 2390.80| |: |?| 0>@11| |%|(
(764) | A""1| |C ||
(765) | 08<>0|. Mar 2009 Mar 2008 Mar 2007 Mar 2006 12| 12| 12| 12| 32107.60| 23027.50| 1729.20| 12638.60| 1|. 1|. 1|. 1|. 1| A">"1| 9"8#1@1|. 1| @A<A1| 008@<#1|. 1| A"9>1| "A<"@@1|. 1| 8<>91| "0"@"91|. |. -202.50| 151.20| 9>9A1| "01011|. | -387.00| 11993.90| 9"1#1| #<#01|. | -572.30| 8881.30| 0@@@1| <01"1|. | .50| 5559.0| "88<1| <0><1|. "#9<@1|. "##"01|. "@08<1|. A01A1|. <<A11|. A##@1|. 8<#@1|. A8A01|. "<#<11|. "891@1|. "01>>1|. >0"91|. "8A<1|. ">"11|. "@<#1|. 9<1>1|. 1|. 1|. 1|. 1|. 0"A<9A1| #<1A#1| 1326.80| """99>1| @1A1| ""1<9"1| @A""1|. ">"##01| @0@#>1| 1696.0| A#@A"1| <<11| A<A<"1| 8A0>1|. "0>A@@1| 81@111| 1356.0| @81A81| ""091| @0#8"1| 81>91|. <#1@91| 908A11| 31.80| 9A>><1| ""8>1| 9@A9"1| 90<91|. "1@0011|. A81@81|. 8<<A<1|. 9098<1|. 1|. 1|. 1|. 1|. "1@0011| 381.60| "1"8181| 1688.80| 0"111| 8<#A| 019"@|. A81@81| 116.10| A0<#91| 10192.00| "9@11| 90@0| "0A@<|. 8<<A<1| 273.90| 8A"0#1| 7207.0| ""111| 08<8| ><<1|. 9098<1| 177.70| 91@>"1| 96.70| >@11| "A8<| @#@"|. | | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(766) | |. |. Balae shee|G| |A|G||||||||||||||||||||||||||||||||||||||||||||||||2|| | Pari lars SOURCES Oô ôUNDS (
(767) |) |. Mar 2009. Mar 2008. Mar 2007. Mar 2006. | 1035.60|. |. | 980.70|. | 92.70|. | 91.60|. ! |2|. 5078.60|. 100.60|. 2351.20|. 13706.70|. 10112.80|. (
(768)
(769) |. | ( |O| ' |O| Toal Debs Toal Liabiliies APPLICATION Oô ôUNDS|G|. @"@"801| 236.00| 0| 09A11| @">@101|. 801>A01| 228.80| 796.0| "10@01| 89"1"81|. 088#8#1| 203.90| 1077.60| "1A<"@1| 9@">A81|. "8A8#81| 182.30| 17275.90| ">8@<01| 90"1>A1|. ""1@8@1| 139.20| 18007.30| "<"8A@1| 0#01"11|. |. |. |. |. |. 4| |. "1A"#11|. #9@191|. <9<>11|. >880A1|. A"01@1|. OG| | : |. 9A0A81|. 918##1|. 08#8"1|. 01<1>1|. ">0#11|. / | |. A##0A1|. A91181|. @<#0#1|. @9A"#1|. 89#"@1|. >@#@1|. 99891|. 9"#"1|. 91<11|. 8>#81|. 1|. 1|. 1|. 1|. 1|. 2695.90|. 1835.70|. 1057.90|. 7796.20|. 9852.0|. | 867.0| 6800.30| "0A@8>1| @"0A1| 90<A@1| 0<"0"@1|. | 3896.30| 1055.0| "1>0801| 0@><1| 9A"<>1| 0#1@"81|. | 3333.80| 568.70| "010A<1| 90>11| 91<A<1| 08809"1|. | 263.10| 256.70| "091<01| ">@@1| 8<#101| 00@>0>1|. | 1866.20| 239.70| <#1191| 8@11| 89<8"1| ">@8@91|. | 5730.90| 16.20| #<#@"1| "<00A81| @<91|. | 7263.10| 2627.90| #<#"11| "#"A181| A8<1|. | 863.0| 77.00| 8#8181| "#8<0>1| 8881|. | 1661.80| 1225.00| 0<<A<1| "#A<@#1| 0A<1|. | 1370.10| 8.50| 00"8A1| "@991>1| 0A81|. "090@1|. ""#801|. ""9>A1|. "1>"01|. <>#81|. ) |6| | % | %- | +| | | ) | |O| F| | | ( |: | )
(770) || | 7
(771) |) | | O|| | ! |) | | O|G|)|O|| % | ) |O | % | ! |) |O | / |) | | :|!+| | :|!+|O |. Mar 2010. 1035.60|. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(772) | |. |. :|!+| |B| O | Toal Asses ) |O |. -"">801|. -""0#81|. -"1#901|. -"18881|. -<@911|. @">@101| "10001|. 89"1"81| >9"@1|. 9@">A81| """9"1|. 90"1>A1| A<A<1|. 0#01"11| @A>11|. | |. G| | ( |%
(773) | |00|?| ||,--,| ||
(774) |011#| |
(775) | 01"1| | )| | | |% !||08>|?||| | || | : | | |% !||||
(776)
(777) | || %(|
(778) | | ||0@|?||,--,| ||
(779) |011#-|
(780) |01"1| | )|
(781) | || | | |
(782) |
(783) || | | | | || ||| |||| |||
(784) | | |
(785) || | ( |||
(786) |
(787) | | ||2|<A8#| | |01|?| ||| | || | | | || | )E| |
(788) |||| | || | | || | |||| | | |. Cash ôlow Saeme: !|>||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||$2 | & |. | SUN PHARMACEUTICALS INDUSTRIES LIMITED. |.
(789) | |. |. Pari lars Profi Before Tax| Adj sme| Chages I workig Capial| Cash ôlow afer hages i Workig Capial| Cash ôlow from Operaig Aivies| Cash ôlow from Ivesig Aiviies| Cash ôlow from ôiaig Aivies| Ne Cash Iflow / O flow| Opeig Cash & Cash E ivales| )
(790) |F|)
(791) | || |B|!||B| | )
(792) |F|)
(793) | || ( | | | ||. | +
(794) | . | ) |)
(795) |F|)
(796) | |. Mar 2010 Mar 2009 Mar 2008 Mar 2007 Mar 2006 1295.00| 10522.00| 605.0| 886.80| 323.80| -113.50| -197.10| -969.20| -590.30| 233.20| 1075.50| -3612.00| -776.00| -103.70| -1170.80| 12616.00|. 6712.90| 660.20|. 3261.80|. 2297.20|. 1262.90| 6261.30| 505.60| -6603.70| -73.90| -1125.80| -3256.70| -60.60| -360.80| 276.50| -123.20| -225.00| 9773.10| 1208.80| 12309.80|. 3108.30| 1607.60| -1308.00| 307.90| 8900.30|. 2198.10| -863.0| 1578.90| 812.60| 757.50|. 1|. 1|. 1|. 1|. 101|. 1|. 1|. 1|. 1|. 1|. 1|. 1|. 1|. 1|. 1|. "0@9>A1| "1<@1A1| "01<8<1| "091<01| <#1191|. ||. | )
(797) ||| | |
(798) | | | | ||| | || |
(799)
Related documents
Those students who reported they would not enroll in a distance education course using only WebCT as their only contact with the instructor (42.1%) cited reasons such as: “I like
Recalling that the basic A-type sLag also has a vanishing Chern-Simons invariant, we therefore conclude that all the Chern-Simons invariants vanish and we can write down the full
A comparison of the retrieval performances between the expanded query language model using the query- specific optimal numbers of feedback documents (based on Figure 1(a)) versus
The findings from research question three showed that overrepresented students in AP classes, Whites and Asians, scored higher on the PASS, and thus felt their school had a more
SP3524A Managed VDSL Switch, QAM, 4-band VDSL, 24 VDSL lines, 2 Gigabit Ethernet ports SP3501BM/SP3501BS VDSL2 CO/CPE Modem Router, ITU-T G.993.2, up to 100/100Mbps SP3501AS
In the Roman world which largely defined the socio-historical context of Romans 1 and Wisdom 14, notions of appropriate religious expression and virtuous sexual behaviour were
Bilbo was sitting on the water’s brink, at the end of his way and his wits, when up paddled Gollum, his eyes glowing softly in the dark?. NARRATOR 2: Bilbo jumped nearly out of
The results showed that only one Puskesmas reported on Monday morning where the accuracy of the reports reached 100%. This is in accordance with the indicator of
